Johnson & Johnson (JNJ) : Pacad Investment Ltd. added new position in Johnson & Johnson during the most recent quarter end. The investment management firm now holds 42,492 shares of Johnson & Johnson which is valued at $5,235,864 , the company said in a statement filed on Aug 11, 2016 with the SEC.Johnson & Johnson makes up approximately 0.69% of Pacad Investment Ltd.’s portfolio.
Other Hedge Funds, Including , Teachers Advisors Inc reduced its stake in JNJ by selling 176,956 shares or 3.56% in the most recent quarter. The Hedge Fund company now holds 4,799,998 shares of JNJ which is valued at $591,455,754. Johnson & Johnson makes up approx 0.99% of Teachers Advisors Inc’s portfolio.Mengis Capital Management reduced its stake in JNJ by selling 300 shares or 0.95% in the most recent quarter. The Hedge Fund company now holds 31,165 shares of JNJ which is valued at $3,857,292. Johnson & Johnson makes up approx 3.27% of Mengis Capital Management’s portfolio.Harel Insurance Investments Financial Services Ltd. boosted its stake in JNJ in the latest quarter, The investment management firm added 5,214 additional shares and now holds a total of 5,416 shares of Johnson & Johnson which is valued at $671,042. Johnson & Johnson makes up approx 0.08% of Harel Insurance Investments Financial Services Ltd.’s portfolio.Sol Capital Management Co reduced its stake in JNJ by selling 1,225 shares or 8.38% in the most recent quarter. The Hedge Fund company now holds 13,391 shares of JNJ which is valued at $1,676,955. Johnson & Johnson makes up approx 0.50% of Sol Capital Management Co’s portfolio.Bartlett reduced its stake in JNJ by selling 842 shares or 0.58% in the most recent quarter. The Hedge Fund company now holds 143,681 shares of JNJ which is valued at $17,927,078. Johnson & Johnson makes up approx 0.86% of Bartlett’s portfolio.
Johnson & Johnson opened for trading at $119.67 and hit $119.96 on the upside on Tuesday, eventually ending the session at $119.44, with a gain of 0.26% or 0.31 points. The heightened volatility saw the trading volume jump to 56,03,177 shares. Company has a market cap of $326,773 M.
On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.